Literature DB >> 28077639

Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.

Flavia Chiuppesi1, Teodora Kaltcheva1, Zhuo Meng1, Peter A Barry2, Don J Diamond3, Felix Wussow3.   

Abstract

As human cytomegalovirus (HCMV) is the most common infectious cause of fetal anomalies during pregnancy, development of a vaccine that prevents HCMV infection is considered a global health priority. Although HCMV immune correlates of protection are only poorly defined, neutralizing antibodies (NAb) targeting the envelope pentamer complex (PC) composed of the subunits gH, gL, UL128, UL130, and UL131A are thought to contribute to the prevention of HCMV infection. Here, we describe a continuous target sequence within UL128 that is recognized by a previously isolated potent PC-specific NAb termed 13B5. By using peptide-based scanning procedures, we identified a 13-amino-acid-long target sequence at the UL128 C terminus that binds the 13B5 antibody with an affinity similar to that of the purified PC. In addition, the 13B5 binding site is universally conserved in HCMV, contains a previously described UL128/gL interaction site, and interferes with the 13B5 neutralizing function, indicating that the 13B5 epitope sequence is located within the PC at a site of critical importance for HCMV neutralization. Vaccination of mice with peptides containing the 13B5 target sequence resulted in the robust stimulation of binding antibodies and, in a subset of immunized animals, in the induction of detectable NAb, supporting that the identified 13B5 target sequence constitutes a PC-specific neutralizing epitope. These findings provide evidence for the discovery of a continuous neutralizing epitope within the UL128 subunit of the PC that could be an important target of humoral immune responses that are involved in protection against congenital HCMV infection.IMPORTANCE Neutralizing antibodies (NAb) targeting the human cytomegalovirus (HCMV) envelope pentamer complex (PC) are thought to be important for preventing HCMV transmission from the mother to the fetus, thereby mitigating severe developmental disabilities in newborns. However, the epitope sequences within the PC that are recognized by these potentially protective antibody responses are only poorly defined. Here, we provide evidence for the existence of a highly conserved, continuous, PC-specific epitope sequence that appears to be located within the PC at a subunit interaction site of critical importance for HCMV neutralization. These discoveries provide insights into a continuous PC-specific neutralizing epitope, which could be an important target for a vaccine formulation to interfere with congenital HCMV infection.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HCMV; UL128; epitope; pentamer complex; peptide

Mesh:

Substances:

Year:  2017        PMID: 28077639      PMCID: PMC5331811          DOI: 10.1128/JVI.01857-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

3.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

4.  Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes.

Authors:  Claudio Ciferri; Sumana Chandramouli; Danilo Donnarumma; Pavel A Nikitin; Michael A Cianfrocco; Rachel Gerrein; Adam L Feire; Susan W Barnett; Anders E Lilja; Rino Rappuoli; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

5.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

6.  Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.

Authors:  Anna Kabanova; Laurent Perez; Daniele Lilleri; Jessica Marcandalli; Gloria Agatic; Simone Becattini; Silvia Preite; Dario Fuschillo; Elena Percivalle; Federica Sallusto; Giuseppe Gerna; Davide Corti; Antonio Lanzavecchia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

7.  Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.

Authors:  S B Boppana; W J Britt
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

8.  Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.

Authors:  Daniele Lilleri; Anna Kabanova; Antonio Lanzavecchia; Giuseppe Gerna
Journal:  J Clin Immunol       Date:  2012-07-27       Impact factor: 8.317

9.  Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.

Authors:  Yingxia Wen; James Monroe; Christine Linton; Jacob Archer; Clayton W Beard; Susan W Barnett; Giuseppe Palladino; Peter W Mason; Andrea Carfi; Anders E Lilja
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

Review 10.  Desirability and feasibility of a vaccine against cytomegalovirus.

Authors:  Paul Griffiths; Stanley Plotkin; Edward Mocarski; Robert Pass; Mark Schleiss; Philip Krause; Stephanie Bialek
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

View more
  7 in total

Review 1.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

2.  Human Cytomegalovirus Particles Treated with Specific Antibodies Induce Intrinsic and Adaptive but Not Innate Immune Responses.

Authors:  Zeguang Wu; Ruifang Qin; Li Wang; Matteo Bosso; Myriam Scherer; Thomas Stamminger; Dominik Hotter; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

3.  Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.

Authors:  Flavia Chiuppesi; Jenny Nguyen; Felix Wussow; Don J Diamond; Soojin Park; Heidi Contreras; Mindy Kha; Zhuo Meng; Teodora Kaltcheva; Angelina Iniguez; Joy Martinez; Corinna La Rosa
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

4.  Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex.

Authors:  Felix Wussow; Flavia Chiuppesi; Zhuo Meng; Joy Martinez; Jenny Nguyen; Peter A Barry; Don J Diamond
Journal:  J Virol Methods       Date:  2017-10-06       Impact factor: 2.014

5.  Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.

Authors:  Weixu Meng; Aimin Tang; Xiaohua Ye; Xun Gui; Leike Li; Xuejun Fan; Robbie D Schultz; Daniel C Freed; Sha Ha; Dai Wang; Ningyan Zhang; Tong-Ming Fu; Zhiqiang An
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.

Authors:  Flavia Chiuppesi; Felix Wussow; Louise Scharf; Heidi Contreras; Han Gao; Zhuo Meng; Jenny Nguyen; Peter A Barry; Pamela J Bjorkman; Don J Diamond
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

7.  An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies.

Authors:  Mohammad Amin Behzadi; Kathryn R Stein; Maria Carolina Bermúdez-González; Viviana Simon; Raffael Nachbagauer; Domenico Tortorella
Journal:  Vaccines (Basel)       Date:  2019-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.